João Cristina, Costa Carlos, Coelho Inês, Vergueiro Maria João, Ferreira Mafalda, da Silva Maria Gomes
Department of Hematology, IPOFG Lisboa, Portugal ; Clinical Research Unit, IPOFG Lisboa, Portugal.
Department of Hematology, IPOFG Lisboa, Portugal.
Clin Case Rep. 2014 Oct;2(5):173-9. doi: 10.1002/ccr3.76. Epub 2014 May 28.
The survival of multiple myeloma patients has improved very significantly over the last decade. Still median overall survival is inferior to 5 years. A small proportion of patients survive longer than 10 years. In this paper we discuss four cases illustrating the nonhomogeneous clinical presentation and evolution of this subset of patients. Surprisingly, these long survivors do not always have deep responses and some require frequent treatments, which include autologous stem cell transplantation and novel drugs. The authors discuss several aspects of these clinical histories, including treatment options, raising hypothesis on their relation with long survivorship which may be important to have in consideration when studying this subject.
在过去十年中，多发性骨髓瘤患者的生存率有了显著提高。然而，总体中位生存期仍不足5年。一小部分患者存活时间超过10年。在本文中，我们讨论了4例病例，以说明这一亚组患者的非均一临床表现和病程演变。令人惊讶的是，这些长期存活者并不总是有深度缓解，有些患者需要频繁治疗，包括自体干细胞移植和新型药物。作者讨论了这些临床病史的几个方面，包括治疗选择，提出了关于它们与长期生存关系的假设，这在研究该主题时可能是需要考虑的重要因素。
